When was Harmony Biosciences founded?

Harmony Biosciences was founded in 2017 and raised its 1st funding round within a year of its incorporation.

Where is Harmony Biosciences located?

Harmony Biosciences is headquartered in Plymouth Meeting, United States.

Who is the current CEO of Harmony Biosciences?

Bob Repella of Harmony Biosciences.

How many employees does Harmony Biosciences have?

As of May 31, 2026, the latest employee count at Harmony Biosciences is 338.

Is Harmony Biosciences a funded company?

Harmony Biosciences is a funded company, having raised a total of $345M across 6 funding rounds to date. The company's 1st funding round was a $***** Series D round, raised on Sep 22, 2017.

When was the latest funding round of Harmony Biosciences?

Harmony Biosciences' latest funding was a $***** Conventional Debt round on Jan 27, 2020, with participation from 1 investor.

What is the annual revenue of Harmony Biosciences?

Annual revenue of Harmony Biosciences is $868M as on Dec 31, 2025.

Where does Harmony Biosciences rank among its competitors?

Harmony Biosciences ranks 3rd amongst 54 active competitors, of which 17 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was AcuraStem, which secured $7.5M in Apr, 2026.

Who are the top competitors of Harmony Biosciences?

Harmony Biosciences' top competitors include Passage Bio, Evox Therapeutics and Mammoth. Among them, AcuraStem secured the most recent funding round in April, 2026.

Harmony Biosciences - 2026 Company Profile, Team, Funding, Competitors & Financials

Harmony Biosciences is a public company based in Plymouth Meeting (United States), founded in 2017. It operates as a Developer of therapeutics for rare neurological diseases. Harmony Biosciences has raised $345M in funding from investors like Fidelity Investments, Aisling Capital and VenBio. The company has 54 active competitors, including 17 funded and 16 that have exited. Its top competitors include companies like Passage Bio, Evox Therapeutics and Mammoth.

Company Details

Developer of therapeutics for rare neurological diseases. The company is engaged in the research, development, and commercialization of novel treatments for rare diseases mainly CNS disorders including Wakix for Narcolepsy.

Website: harmonybiosciences.com
Email ID: *****@harmonybiosciences.com
Part Of

Key Metrics

Founded Year

2017

Location

Plymouth Meeting, United States

Stage

Public

Total Funding

$345M in 6 rounds

Latest Funding Round

Conventional Debt, Jan 27, 2020, $*****

Investors

Fidelity Investments & 13 more

Ranked

3^rd among 54 active competitors

Annual Revenue

$868M as on Dec 31, 2025

Employee Count

338 as on May 31, 2026

Investment & Acquisitions

Zynerba Pharma

Similar Companies

Passage Bio & 59 more

Exit Details

Public

View Harmony Biosciences' full profile

Harmony Biosciences is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Harmony Biosciences, LLC CIN: 82-1608705 , United States, Active	May 16, 2017	-	180 (As on Dec 31, 2021)	-
HARMONY BIOSCIENCES HOLDINGS, INC. CIN: 1802665 , United States, Active	Jul 24, 2017	$868M (As on Dec 31, 2025)	246 (As on Dec 31, 2023)	-
Harmony Biosciences Llc CIN: 821608705 , United States, Active	Dec 31, 1999	-	269 (As on Dec 31, 2024)	-

Harmony Biosciences got listed on Aug 19, 2020.

Click here to take a look at Harmony Biosciences's IPO in detail

Harmony Biosciences has raised a total funding of $345M over 6 rounds. Its first funding round was on Sep 22, 2017. Its latest funding round was a Conventional Debt round on Jan 27, 2020 for $*****. 1 investor participated in its latest round. Harmony Biosciences has 14 institutional investors.

Here is the list of recent funding rounds of Harmony Biosciences:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 27, 2020	4198565	Conventional Debt	4637258	8222400	3581729	9410807
Aug 09, 2019	3780443	Series E	8498045	5712225	7479146	4569837
Mar 13, 2019	3183606	Conventional Debt	1382671	9240493	8922610	CRG

Access funding benchmarks and valuations. Sign up today!

View details of Harmony Biosciences's funding rounds and investors

Harmony Biosciences' employee count trend

Harmony Biosciences has 338 employees as of May 26. Here is Harmony Biosciences's employee count trend over the years:

Employee count trend for Harmony Biosciences

Uncover Harmony Biosciences' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Harmony Biosciences include Passage Bio, Evox Therapeutics and Mammoth. Here is the list of Top 10 competitors of Harmony Biosciences, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Passage Bio 2017, Philadelphia (United States), Public	Developer of gene therapies for CNS rare diseases	$226M	Access Biotechnology, Orbimed & 10 others	69/100
2nd	Evox Therapeutics 2016, Oxford (United Kingdom), Series C	Developer of exosome-based therapeutics for severe neurological and rare diseases	$156M	Redmile Group, Gates & 26 others	66/100
3rd	Harmony Biosciences 2017, Plymouth Meeting (United States), Public	Developer of therapeutics for rare neurological diseases	$345M	Fidelity Investments, Newlight Partners & 12 others	66/100
4th	Mammoth 2017, Brisbane (United States), Series D	Provider of molecular diagnostics platform by using CRISPR technology	$271M	Redmile Group, Decheng Capital & 34 others	65/100
5th	Ovid Therapeutics 2014, New York City (United States), Public	Developer of therapeutics for rare neurological diseases	$106M	Fidelity Investments, Cowen & 6 others	65/100
6th	QurAlis 2016, Cambridge (United States), Series B	Developing drugs & CSF cartridge device for treating amyotrophic lateral sclerosis (ALS)	$155M	Amgen Business Development, Acks & 21 others	63/100
7th	Neurogene 2001, New York City (United States), Public	Developer of therapeutics for the treatment of rare neurological disorders	$184M	EcoR1, Samsara BioCapital & 8 others	60/100
8th	Retrotope 2006, Los Altos (United States), Acquired	Developer of therapeutics to treat neurodegenerative and ophthalmological diseases	$69.6M	SDL Ventures, Green Park & Golf Ventures ... & 12 others	53/100
9th	Tisento Therapeutics 2023, Cambridge (United States), Series A	Developer of therapeutics for the treatment of rare genetic diseases	$81M	J. Wood Capital Advisors, Invus & 2 others	51/100
10th	AcuraStem 2016, Monrovia (United States), Seed	Developer of therapeutics for neurodegenerative diseases	$780K	CIRM, Defense.gov & 5 others	51/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Harmony Biosciences's competitors? Click here to see the top ones

Harmony Biosciences has acquired Zynerba Pharma. Harmony Biosciences has not made any investments as of now.

Media has covered Harmony Biosciences for a total of 30 events in the last 1 year, 23 of them have been about company updates and 1 about partnerships.